Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-10), Qol Holdings Co's 1-Year Sharpe Ratio is 0.59.
Qol Holdings Co (TSE:3034) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Qol Holdings Co 1-Year Sharpe Ratio Related Terms
Qol Holdings Co 1-Year Sharpe Ratio Competitor Comparison
For the Pharmaceutical Retailers subindustry, Qol Holdings Co's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qol Holdings Co 1-Year Sharpe Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qol Holdings Co's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Qol Holdings Co's 1-Year Sharpe Ratio falls into.
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Qol Holdings Co (TSE:3034) has a 1-Year Sharpe Ratio of 0.59 as of Sep. 10, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Qol Holdings Co and its competitors.
Is Qol Holdings Co's 1-Year Sharpe Ratio too high?
Qol Holdings Co's current 1-Year Sharpe Ratio is 0.59. Overall, Qol Holdings Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Qol Holdings Co's 1-Year Sharpe Ratio compare to competitors?
Qol Holdings Co's 1-Year Sharpe Ratio of 0.59 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Healthcare Providers & Services company?
A good 1-Year Sharpe Ratio depends on the Healthcare Providers & Services industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Qol Holdings Co and its competitors. Qol Holdings Co's current 1-Year Sharpe Ratio is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qol Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Qol Holdings Co (TSE:3034) is currently considered Fairly Valued. The stock's GF Value™ is 円2,303.99, compared to a current price of 円2,218.00 — trading 3.7% below its estimated fair value. The current 1-Year Sharpe Ratio is 0.59. Qol Holdings Co's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Qol Holdings Co (TSE:3034), the current 1-Year Sharpe Ratio is 0.59 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qol Holdings Co (TSE:3034) Overvalued in 2026?
Based on GuruFocus' analysis, Qol Holdings Co stock appears to be undervalued.
The current stock price of 円2,218.00 is trading 3.7% below its estimated GF Value™ of 円2,303.99.
GuruFocus considers Qol Holdings Co to be Fairly Valued.
Key valuation signals for TSE:3034:
1-Year Sharpe Ratio: 0.59
GF Value™: 円2,303.99 vs. price of 円2,218.00 (3.7% below fair value)
No single metric tells the full story. See the TSE:3034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qol Holdings Co Ltd provides pharmacy services under health insurance and sells pharmaceutical products. Its mission is to create healthy and comfortable living environments for everybody in those communities. The company operates through: Pharmacy and BPO segments. Under the Pharmacy segment the company puts customers first in-store development strategy, which is based on building one-on-one relationships with drug-prescribing clinics and hospitals in order to get the pharmacy services that include medical information. The BPO contracting segment includes clinical trials and projects and develops pamphlets and websites for medical institutions to promote sales of pharmaceutical products and provide advice on proper pharmaceutical product.
86GF Score
Get the complete analysis for TSE:3034
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3034 has been successfully added to your 
